ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-OR66

Proenkephalin A 119-159 as a Novel Biomarker for Early Detection of Delayed Graft Function After Kidney Transplantation

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Nusshag, Christian, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Benning, Louise, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Göth, Daniel, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Mahler, Christoph Friedrich, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Kälble, Florian, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Speer, Claudius, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Reineke, Marvin, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Schmitt, Felix C.F., Heidelberg University Hospital Department of Anesthesiology, Heidelberg, Germany
  • Mieth, Markus, Heidelberg University Hospital Department of General, Visceral and Transplantation Surgery, Heidelberg, Germany
  • Zeier, Martin G., Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany
  • Mehrabi, Arianeb, Heidelberg University Hospital Department of General, Visceral and Transplantation Surgery, Heidelberg, Germany
  • Weigand, Markus A., Heidelberg University Hospital Department of Anesthesiology, Heidelberg, Germany
  • Morath, Christian, Heidelberg University Hospital Department of Nephrology, Heidelberg, Germany

Group or Team Name

  • Group Nusshag.
Background

Delayed graft function (DGF) frequently occurs following kidney transplantation and adversely affects patient outcomes such as length of hospital stay, impaired long-term graft function and ultimately quality of life. Though a universal definition of DGF is lacking, a common classification is the need for dialysis in the first postoperative week excluding the first 24 hours. The aim of this study was to evaluate the capabilities of the novel kidney function biomarker proenkephalin A 119-159 (penKid) to predict DGF compared to serum creatinine (SCr).

Methods

In the currently ongoing study, penKid has been quantified from plasma using a chemiluminescence immunoassay in our daily routine in all freshly transplanted patients since November 2022. PenKid is quantified the day of transplantation and every weekday following transplantation. For this preliminary analysis, penKid levels were compared to SCr. The end of data collection is June 30, 2023.

Results

In a preliminary analysis including 70 kidney transplant recipients (70% cadavric transplants), results suggest, that penKid may discriminate patients with delayed graft function from patients with primary graft uptake earlier than SCr. In contrast to SCr, penKid was able to distinguish between DGF and no DGF as early as 24 hours after transplantation (Figure 1). In addition, other than SCr, penKid levels do not seem to be affected by dialysis.

Conclusion

PenKid is a promising new biomarker for the early prediction of DGF after kidney transplantation and may enable clinicians to adjust their treatment in high-risk patients accordingly. However, more clinical data is needed to validate our findings and to establish the clinical utility of penKid in the management of kidney transplant patients.